Cited by Future Barriers and Possible Solutions with Recent Advances in Alzheimer’s Disease

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough DOI

Rishabh,

Manni Rohilla, Seema Bansal

et al.

European Journal of Neuroscience, Journal Year: 2024, Volume and Issue: 60(1), P. 3466 - 3490

Published: May 10, 2024

Abstract In females, Alzheimer's disease (AD) incidences increases as compared to males due estrogen deficiency after menopause. Estrogen therapy is the mainstay for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. plays crucial role amyloid precursor protein (APP) processing overall neuronal health by regulating various factors such brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes apolipoprotein E (ApoE) polymorphisms. All these impact physiology of postmenopausal women. replacement therapies play an important treatment strategy prevent However, use may lead increased risks breast cancer, venous thromboembolism cardiovascular disease. Various therapeutic approaches have used mitigate effects on AD. These include therapy, Selective Receptor Modulators (SERMs), Beta (ERβ)‐Selective Agonists, Transdermal Delivery, Localised Combination Therapies, Metabolism Modulation Alternative Estrogenic Compounds like genistein from soy, notable phytoestrogen plant sources. mechanism via which modulate women not explained earlier thoroughly. Present review will enlighten all molecular mechanisms Along‐with this, association between estrogen, ApoE polymorphisms also be discussed

Language: Английский

Citations

Exploring acridine-quinolinium conjugates as near-infrared photosensitizers for the Amyloid-β photo-oxidation DOI

Yi-jiao He,

Wen-jing Shi, Jinwu Yan

et al.

Sensors and Actuators B Chemical, Journal Year: 2025, Volume and Issue: unknown, P. 137233 - 137233

Published: Jan. 1, 2025

Language: Английский

Citations

CD34+ Hematopoietic Stem Cell Counts in Alzheimer’s Disease: A Meta-Analysis DOI

Vinay Suresh, Malavika Rudrakumar,

Anmol Kaur

et al.

Diseases, Journal Year: 2025, Volume and Issue: 13(2), P. 25 - 25

Published: Jan. 21, 2025

Purpose: To assess the presence and quantity of CD34+ hematopoietic stem cells in patients with Alzheimer’s disease (AD) through a meta-analysis. Methods: A systematic search databases identified observational interventional studies reporting baseline cell counts AD patients. The data on mean measures variation were extracted. Standardized differences (SMDs) calculated using common random effects models to compare between controls. Heterogeneity among was evaluated tau2, tau, I2 statistics. risk bias assessed Newcastle–Ottawa Scale ROBINS-I tool. Patients: Five included, comprising four one open-label trial, total 271 participants (139 132 controls). Results: meta-analysis indicated an increase when compared model showed moderate SMD 0.2964 (95% CI:0.0490–0.5437). However, yielded non-significant 0.2326 CI: −0.4832–0.9484). Significant heterogeneity observed (I2 = 87.1%, p < 0.0001). Conclusion: may exhibit higher circulating than controls, but substantial potential biases limit definitive conclusions.

Language: Английский

Citations

Gegen Qinlian Decoction improves Alzheimer’s disease through TLR4/NF-κB/NLRP3 pathway DOI

Bin Zhang,

Liudan Chen,

Mengru Kang

et al.

Tissue and Cell, Journal Year: 2025, Volume and Issue: 95, P. 102818 - 102818

Published: March 1, 2025

Language: Английский

Citations

The role of fusion proteins as biomarkers and therapeutic agents for Alzheimer's disease: A narrative review DOI

Dessy Agustini,

Rohan Sabloak,

Shemonti Hasan

et al.

NeuroMarkers., Journal Year: 2025, Volume and Issue: 2(2), P. 100041 - 100041

Published: March 8, 2025

Language: Английский

Citations

Salutary effects of transdermal curcumin on multiple indices of health span in rodent models of normal aging and hypertension DOI

Kai Mao,

Ruixuan Wang,

Kateryna Karpoff

et al.

GeroScience, Journal Year: 2025, Volume and Issue: unknown

Published: March 15, 2025

Abstract Geroscience has helped to usher in a new and exciting era of aging drug development evaluation novel repurposed agents, as well natural compounds purported target one or more hallmarks. Among the latter, curcumin long been pursued promising strategy but failed provide convincing evidence human trials. Oral intake is typical route administration tested for vast majority gerotherapeutic candidates, including curcumin, efficacy dependent upon good oral bioavailability pharmacokinetics. However, unlike FDA-approved medications, many compounds, such have poor bioavailability, which may explain their limited success translation. To overcome these inherent limitations, we solvent-based formulation concentrated (VASCEPTOR®), developed effective skin penetration delivery high amounts bioactive curcuminoids directly circulation on age-related conditions. We demonstrate that short-term topical treatment (7.5 mg per dose) with VASCEPTOR® twice week can improve both vascular health rat model hypertension, while late-life intervention aged mice improves multiple indices span, improved exercise tolerance, motor coordination, diastolic function ( p < 0.05), reduction frailty status 0.05) expression some markers tissues, particular heart kidney. Thus, data suggest therapeutic potential potentially be dramatically enhanced by and, along other should prioritized further development, testing deployment manifestations humans.

Language: Английский

Citations

Yoga an integrated mind body intervention for improvement in quality of life in individuals with Alzheimer’s disease and their caregivers DOI

Meenakshi Kaushik,

Anjali Yadav, Abhinav Upadhyay

et al.

Frontiers in Aging, Journal Year: 2025, Volume and Issue: 6

Published: March 21, 2025

Background and objective Alzheimer’s disease (AD) presents profound challenges, significantly impairing quality of life (QOL) for patients increasing the burden on caregivers. This study aims to investigate effectiveness a tailored 12-week yoga intervention in improving individuals with mild moderate AD reducing caregiver (CB). Methods is interventional healthy controls enrolled 30 participants (18 males, 12 females) diagnosed by an expert neurologist. Participants were aged 60 years or older recruited from old age home. A program, including specific postures (asanas), pranayama (breathing exercises), meditation, was conducted 1 hour daily, 6 days week. Neurocognitive assessments performed pre- post-intervention using Geriatric Depression Scale (GDS), Montreal Cognitive Assessment (MoCA), Caregiver Burden (CB) Scale. MoCA scores analyzed across domains, language, memory, attention, visuospatial ability, delayed recall, abstraction, orientation. Results The led significant improvements quality-of-life measures. GDS decreased 8.36 ± 2.79 5.13 3.07 (P < 0.01; 95% CI: −3.98 −2.31), while total improved 18.23 4.90 21.10 5.09 2.17–3.89). Domain-specific also showed enhancements, particularly recall. burden, measured CB Scale, demonstrated notable reductions following −2.54 −1.23). Conclusion underscores depression cognitive function, overall AD. Additionally, alleviated highlighting its potential as effective mind-body approach management.

Language: Английский

Citations

A calmodulin-derived peptide TI-16 inhibits alzheimer's disease progression by decreasing aβ burden and restoring calcium dyshomeostasis DOI

Jingyang Su,

Jun Wei, Bowen Zhang

et al.

Bioorganic Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 108502 - 108502

Published: April 1, 2025

Language: Английский

Citations

Role of curcumin on beta-amyloid protein, tau protein, and biochemical and oxidative changes in streptozotocin-induced diabetic rats DOI

Mustafa Ermiş, Gülay Çiftçi

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: 397(12), P. 9833 - 9844

Published: June 26, 2024

Abstract Diabetes is one of the most common endocrine metabolic diseases and associated with accumulation beta-amyloid plaques in brain. Amyloid beta (Aβ) abnormal tau proteins are effective development Alzheimer’s disease. The aim this study to investigate therapeutic protective effects curcumin on protein expression levels, as well biochemical oxidative changes streptozotocin-induced diabetes rats. comprised five groups, each consisting eight rats: control, diabetic, curcumin, during diabetic induction, post-diabetic induction. Groups 2 4 were administered a single dose 45 mg/kg streptozotocin day 1, while group 5 received it 28. Curcumin was orally via gavage at 100 mg/kg/day for 35 days third, fourth, fifth groups. At end trial (day 35), blood sugar levels insulin resistance similar between control curcumin-treated groups but significantly higher ( P < 0.05). effect tested induction active diabetes. results indicated that rats displayed increased Aβ, protein, total oxidant capacity (TOS) compared Additionally, antioxidant (TAS) lower Aβ both serum brain treated > In addition, TAS following than pre-induction TOS prior However, no significant difference observed above show has an reducing stress caused by increasing activity.

Language: Английский

Citations

Efficacy and Mechanism of Schisandra chinensis Fructus Water Extract in Alzheimer’s Disease: Insights from Network Pharmacology and Validation in an Amyloid-β Infused Animal Model DOI

Hye‐Jeong Yang,

Ting Zhang, Min‐Jung Kim

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(21), P. 3751 - 3751

Published: Oct. 31, 2024

Fructus (SCF) is a traditional medicinal herb containing lignans that improves glucose metabolism by mitigating insulin resistance. We aimed to investigate the therapeutic potential and action mechanism of SCF for Alzheimer's disease (AD) using network pharmacology analysis, followed experimental validation in an AD rat model.

Language: Английский

Citations